Premium
P3‐344: HALF‐CURCUMINOIDS AS POTENTIAL AMYLOID‐BETA PET IMAGING AGENTS
Author(s) -
Yang Jian,
Cheng Ran,
Yang Jing,
Cui Mengchao,
Liang Steven H.,
Ran Chongzhao
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1705
Subject(s) - curcumin , in vivo , imaging agent , chemistry , pet imaging , in vitro , fluorescence , amyloid (mycology) , beta (programming language) , aldehyde , amyloid beta , radiochemistry , pharmacology , positron emission tomography , nuclear medicine , biochemistry , medicine , peptide , inorganic chemistry , physics , microbiology and biotechnology , quantum mechanics , computer science , biology , programming language , catalysis
P3-343 AGE-NORMED DIFFUSION BASIS SPECTRUM IMAGING (DBSI) CELL RATIOS TO ASSESS NEUROINFLAMMATION IN ALZHEIMER’S DISEASE CLINICAL TRIALS Arnaud Charil, Qing Wang, Yong Wang, Tammie L. S. Benzinger, Adam J. Schwarz, Eli Lilly and Company, Indianapolis, IN, USA; Washington University School of Medicine, St. Louis, MO, USA; Washington University in St. Louis School of Medicine, St. Louis, MO, USA. Contact e-mail: arnaud.charil@lilly.com